Skip to content

Ibogaine: all studies

Page 31 of 62: studies 301 to 310 of 613, newest first. Back to the ibogaine overview

Research

Noncompetitive Functional Inhibition at Diverse, Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine

Journal of Pharmacology and Experimental Therapeutics 1999 John Denis Fryer, Ronald J. Lukas 283 citations

Nicotinic acetylcholine receptors (nAChR) are diverse members of the neurotransmitter-gated ion channel superfamily and play critical roles in chemical signaling throughout the nervous system. The present study establishes the acute functional effects of bupropion, phencyclidine, and ibogaine on two human nAChR subtypes. Function of muscle-type nAChR (alpha1 beta gamma delta) in TE671/RD cells...

DOI: 10.1016/s0022-3565(24)37928-5 (opens in new tab) Nicotinic acetylcholine receptor Phencyclidine Pharmacology Nicotinic agonist +7

Treatment of acute opioid withdrawal with ibogaine.

American Journal on Addictions 1999 Kenneth Alper, Howard S. Lotsof, Geerte M. N. Frenken et al. 201 citations

Ibogaine is an alkaloid with putative effect in acute opioid withdrawal. Thirty-three cases of treatments for the indication of opioid detoxification performed in non-medical settings under open label conditions are summarized involving an average daily use of heroin of .64 +/- .50 grams, primarily by the intravenous route. Resolution of the signs of opioid withdrawal without further drug...

DOI: 10.1080/105504999305848 (opens in new tab) Full text (opens in new tab) Ibogaine Acute withdrawal signs Heroin rapid detoxification Significant relief +2

Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.

Journal of Medicinal Chemistry November 5, 1998 Simon M. N. Efange, Deborah C. Mash, A B Khare et al. 33 citations

Five phenyl-substituted derivatives and analogues of 1,2,3,4,5, 6-hexahydroazepino[4,5-b]indole, 5, a major fragment of ibogaine (1), were synthesized and tested for binding to monoamine transporters, the NMDA receptor-coupled cation channel, and dopamine and opioid receptors. All five derivatives, 9 and 17a-d, displayed 8-10-fold higher affinity at the DA transporter than ibogaine and...

DOI: 10.1021/jm980156y (opens in new tab) Full text (opens in new tab) Drug discovery New compounds Novel compounds Synthesized +18

Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice.

Pharmacology November 1, 1998 S Sunder Sharma, Hemendra N. Bhargava 17 citations

The effects of ibogaine, an alkaloid isolated form the bark of the African shrub, Tabernathe iboga, and noribogaine, a metabolite of ibogaine, on morphine antinociception were determined in male Swiss-Webster mice. Mice were rendered tolerant to morphine by implanting them with a pellet containing 25 mg of morphine base for 3 days. Placebo pellet-implanted mice served as controls. The...

Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats.

Brain Research August 3, 1998 D Wei, Isabelle M Maisonneuve, Martin E. Kuehne et al. 48 citations

The iboga alkaloid, ibogaine, its metabolite, noribogaine, and the congener, 18-methoxycoronaridine (18-MC) have all been claimed to have anti-addictive properties in animal models, but the mechanisms underlying these effects are unclear. Ibogaine and noribogaine were shown to have affinity for the serotonin transporter, and inhibition of serotonin reuptake has been proposed to be involved in...

Ibogaine acts at the nicotinic acetylcholine receptor to inhibit catecholamine release.

Brain Research June 22, 1998 S J Mah, Y Tang, P E Liauw et al. 20 citations

In an effort to determine mechanisms of action of the putative anti-addictive agent ibogaine, we have measured its effects on catecholamine release in a model neuronal system, cultured bovine chromaffin cells. Various modes of stimulating catecholamine release were used including nicotinic ACh receptor activation, membrane depolarization with elevated K+ and Na+ channel activation with...

Medication Development of Ibogaine as a Pharmacotherapy for Drug Dependencea.

Annals of the New York Academy of Sciences May 1, 1998 Deborah C. Mash, Craig A. Kovera, Billy E Buck et al. 111 citations

The potential for deriving new psychotherapeutic medications from natural sources has led to renewed interest in rain forest plants as a source of lead compounds for the development of antiaddiction medications. Ibogaine is an indole alkaloid found in the roots of Tabernanthe iboga (Apocynaceae family), a rain forest shrub that is native to equatorial Africa. Ibogaine is used by indigenous...

In Vivo Ibogaine Blockade and In Vitro PKC Action of Cocainea.

Annals of the New York Academy of Sciences May 1, 1998 Emmanuel S Onaivi, Syed F. Ali, Amitabha Chakrabarti 13 citations

Ibogaine may have antiaddiction potential against alcohol, psychostimulant and opiate abuse, but its mechanism of action is unclear. Ibogaine, however, has been demonstrated in numerous studies to have effects in multiple central nervous system (CNS) neurotransmitters systems. We are using in vitro and in vivo systems to study the effects of cocaine and whether these effects can be blocked by...

Effect of Ibogaine on the Various Sites of the NMDA Receptor Complex and Sigma Binding Sites in Rat Braina.

Annals of the New York Academy of Sciences May 1, 1998 Yossef Itzhak, Syed F. Ali 20 citations

Although the alkaloid ibogaine is a potent hallucinogenic agent some indications suggest that it may be useful for the treatment of opioid and cocaine addiction. The neurochemical mechanism(s) underlying ibogaine effects remain unclear. In the present study we investigated the interaction of ibogaine with the phencyclidine (PCP) site located in the ionophore of the N-methyl-d-aspartate (NMDA)...

Mechanisms of Antiaddictive Actions of Ibogainea.

Annals of the New York Academy of Sciences May 1, 1998 Stanley D Glick, Isabelle M Maisonneuve 93 citations

Ibogaine, an alkaloid extracted from Tabemanthe iboga, is being studied as a potential long-acting treatment for oploid and stimulant abuse as well as for alcoholism and smoking. Studies in this laboratory have used animal models to characterize ibogaine's interactions with drugs of abuse, and to investigate the mechanisms responsible. Ibogaine, as well as its metabolite, noribogaine, can...